Skip to main content

Advertisement

SpringerLink
Log in

Increased complexin-1 and decreased miR-185 expression levels in Behçet’s disease with and without neurological involvement

  • Original Article
  • Published:
Neurological Sciences Aims and scope Submit manuscript

Abstract

Although complexin 1 (CPLX1) is not known as an inflammation factor, recent identification of a complexin 1 (CPLX1) polymorphism in Behçet’s disease (BD) has sparked an interest in the role of this molecule in autoinflammation. DNA samples were isolated from peripheral blood mononuclear cells (PBMC) of BD and neuro-Behçet’s disease (NBD) patients and expression levels of CPLX1 and miR-185, a predicted target miRNA for CPLX1 and an inflammation-related miRNA, were investigated by real time PCR assays. PBMC expression levels of CPLX1 were significantly increased in BD and NBD patients. By contrast, levels of miR-185 were reduced in both patient groups. A moderate inverse correlation was found between levels of CPLX1 and miR-185. No correlation could be found between expression levels and clinical features of patients. Significant expression alterations of CPLX1 in BD and NBD patients suggest that this molecule has a proinflammatory action. The putative role of CPLX1 in BD pathogenesis remains to be further studied.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Gül A (2005) Behçet’s disease as an autoinflammatory disorder. Curr Drug Targets Inflamm Allergy 4:81–83

    Article  PubMed  Google Scholar 

  2. Akman-Demir G, Serdaroglu P, Tasçi B (1999) Clinical patterns of neurological involvement in Behçet’s disease: evaluation of 200 patients. The Neuro-Behçet Study Group. Brain 122:2171–2182

    Article  PubMed  Google Scholar 

  3. Remmers EF, Cosan F, Kirino Y et al (2010) Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet’s disease. Nat Genet 42:698–702

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Eastwood SL, Harrison PJ (2001) Synaptic pathology in the anterior cingulate cortex in schizophrenia and mood disorders. A review and a western blot study of synaptophysin, GAP-43 and the complexins. Brain Res Bull 55:569–578

    Article  CAS  PubMed  Google Scholar 

  5. Tannenberg RK, Scott HL, Tannenberg AE, Dodd PR (2006) Selective loss of synaptic proteins in Alzheimer’s disease: evidence for an increased severity with APOE varepsilon4. Neurochem Int 49:631–639

    Article  CAS  PubMed  Google Scholar 

  6. International Study Group for Behçet’s Disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet 335:1078–1080

    Google Scholar 

  7. D’Argenio V, Esposito MV, Telese A et al (2015) The molecular analysis of BRCA1 and BRCA2: next-generation sequencing supersedes conventional approaches. Clin Chim Acta 446:221–225

    Article  PubMed  Google Scholar 

  8. Betel D, Wilson M, Gabow A et al (2008) The microRNA.org resource: targets and expression. Nucleic Acids Res 36:D149–D153

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Kim SK, Nam JW, Rhee JK et al (2006) miTarget: microRNA target gene prediction using a support vector machine. BMC Bioinformatics 7:411

    Article  PubMed  PubMed Central  Google Scholar 

  10. Dweep H, Sticht C, Pandey P, Gretz N (2011) miRWalk-database: prediction of possible miRNA binding sites by “walking” the genes of three genomes. J Biomed Inform 44:839–847

    Article  CAS  PubMed  Google Scholar 

  11. Laganà A, Forte S, Giudice A, et al (2009) miRò: a miRNA knowledge base. Database (Oxford) bap008

  12. Keino H, Watanabe T, Taki W, Okada AA (2011) Effect of infliximab on gene expression profiling in Behcet’s disease. Invest Ophthalmol Vis Sci 52:7681–7686

    Article  CAS  PubMed  Google Scholar 

  13. Archer DA, Graham ME, Burgoyne RD (2002) Complexin regulates the closure of the fusion pore during regulated vesicle exocytosis. J Biol Chem 277:18249–18252

    Article  CAS  PubMed  Google Scholar 

  14. Falkowski MA, Thomas DD, Groblewski GE (2010) Complexin 2 modulates vesicle-associated membrane protein (VAMP) 2-regulated zymogen granule exocytosis in pancreatic acini. J Biol Chem 285:35558–35566

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Cañete JD, Celis R, Noordenbos T et al (2009) Distinct synovial immunopathology in Behçet disease and psoriatic arthritis. Arthritis Res Ther 11:R17

    Article  PubMed  PubMed Central  Google Scholar 

  16. Woska JR Jr, Gillespie ME (2012) SNARE complex-mediated degranulation in mast cells. J Cell Mol Med 16:649–656

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Begemann M, Grube S, Papiol S et al (2010) Modification of cognitive performance in schizophrenia by complexin 2 gene polymorphisms. Arch Gen Psychiatry 67:879–888

    Article  CAS  PubMed  Google Scholar 

  18. Belkaya S, Murray SE, Eitson JL et al (2013) Transgenic expression of microRNA-185 causes a developmental arrest of T cells by targeting multiple genes including Mzb1. J Biol Chem 288:30752–30762

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Belver L, de Yébenes VG, Ramiro AR (2010) MicroRNAs prevent the generation of autoreactive antibodies. Immunity 33:713–722

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Yu M, Liang W, Wen S et al (2014) EphB2 contributes to human naive B-cell activation and is regulated by miR-185. FASEB J 28:3609–3617

    Article  CAS  PubMed  Google Scholar 

  21. Nogales-Gadea G, Ramos-Fransi A, Suárez-Calvet X et al (2014) Analysis of serum miRNA profiles of myasthenia gravis patients. PLoS ONE 9:e91927

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Genetics, Institute for Experimental Medical Research, Istanbul University, Istanbul, Turkey

    Elif Uğurel, Elçin Şehitoğlu & Burçak Vural

  2. Department of Neuroscience, Institute for Experimental Medical Research, Istanbul University, Istanbul, Turkey

    Erdem Tüzün

  3. Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey

    Murat Kürtüncü & Arzu Çoban

Authors
  1. Elif Uğurel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elçin Şehitoğlu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Erdem Tüzün
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Murat Kürtüncü
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Arzu Çoban
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Burçak Vural
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Erdem Tüzün.

Ethics declarations

Conflict of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Uğurel, E., Şehitoğlu, E., Tüzün, E. et al. Increased complexin-1 and decreased miR-185 expression levels in Behçet’s disease with and without neurological involvement. Neurol Sci 37, 411–416 (2016). https://doi.org/10.1007/s10072-015-2419-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-015-2419-3

Keywords

Search

Navigation